There is no evidence from randomised controlled trials that resuscitation with colloids reduces the risk of death, compared to resuscitation with crystalloids, in patients with trauma, burns or following surgery. As colloids are not associated with an improvement in survival, and as they are more expensive than crystalloids, it is hard to see how their continued use in these patients can be justified outside the context of randomised controlled trials.
P L A I N L A N G U A G E S U M M A R Y
No evidence that colloids are more effective than crystalloids in reducing mortality in people who are critically ill or injured Trauma, burns or surgery can cause people to lose large amounts of blood. Fluid replacement, giving fluids intravenously (into a vein) to replace lost blood, is used to try to maintain blood pressure and reduce the risk of dying. Blood products, non-blood products or combinations are used, including colloid or crystalloid solutions. Colloids are increasingly used but they are more expensive than crystalloids. The review of trials found no evidence that colloids reduce the risk of dying compared with crystalloids.
B A C K G R O U N D
Fluid resuscitation for hypovolaemia is a mainstay of the medical management of critically ill patients, whether as a result of trauma, burns, major surgery or sepsis. Although recent studies (Bickell 1994) have suggested that the timing of volume replacement deserves careful consideration, when it comes to selecting the resuscitation fluid clinicians are faced with a range of options. At one level the choice is between a colloid or crystalloid solution. Colloids are widely used, having been recommended in a number of resuscitation guidelines and intensive care management algorithms (Vermeulen 1995; Armstrong 1994) . The US Hospital Consortium Guidelines recommend that colloids are used in haemorrhagic shock prior to the availability of blood products, and in non-haemorrhagic shock following an initial crystalloid infusion. A 1995 survey of US academic health centres, however, found that the use of colloids far exceeded even the Hospital Consortium recommendations (Yim 1995) . Surveys of burn care in the US (Fakhry 1995) and in Australia (Victorian DUAC 1991) found that the use of colloids for resuscitation varied without a set pattern. The choice of fluid has considerable cost implications. Volume replacement with colloids is considerably more expensive than with crystalloids. Clinical studies have shown that colloids and crystalloids have different effects on a range of important physiological parameters. Because of these differences, all-cause mortality is arguably the most clinically relevant outcome measure in randomised trials comparing the two fluid types. Although there have been previous meta-analyses of mortality in randomised trials comparing colloids and crystalloids (Velanovich 1989 , Bisonni 1991 , neither of these satisfy the criteria that have been proposed for scientific overviews (Oxman 1994) , and they predate most of the trials that have been conducted using synthetic colloids, and hypertonic crystalloid solutions. The purpose of this review is to identify and synthesise all available unconfounded evidence of the effect on mortality in critically ill patients of colloids compared to crystalloids for volume replacement.
O B J E C T I V E S
To determine the effects on mortality of using colloids compared to crystalloids, during fluid resuscitation in critically ill patients.
C R I T E R I A F O R C O N S I D E R I N G S T U D I E S F O R T H I S R E V I E W

Types of studies
Controlled trials in which participants were randomised to treatment groups (colloid or control) on the basis of random or quasirandom allocation. As the comparison between fluid type was in terms of effects on mortality, randomised cross-over trials were excluded.
Types of participants
Critically ill patients (excluding neonates) who required volume replacement. Types of participants included were those who were critically ill as a result of trauma, burns, were undergoing surgery, or had other critical conditions such as complications of sepsis.
Preoperative elective surgical patients were excluded.
Types of intervention
The colloids considered were Dextran 70, hydroxyethyl starches, modified gelatins, albumin or plasma protein fraction.
There is overlap between albumin given for volume replacement and albumin given as a nutritional supplement, and many patients with a critical illness have low serum albumin. Where the trial was of total parenteral nutrition with or without albumin, it was excluded. We included trials where the albumin was given as part of volume replacement guided by colloid osmotic pressure or albumin levels.
The control group received crystalloid (isotonic or hypertonic) for fluid replacement. Trials where both groups received blood were included.
Trials of fluids used for other purposes were excluded. For example, trials of pre-loading in preparation for elective surgery, and trials in patients undergoing fluid loading before cardiopulmonary bypass, were excluded.
Types of outcome measures
The principal outcome measure was mortality from all causes, assessed at the end of the follow-up period scheduled for each trial.
S E A R C H M E T H O D S F O R I D E N T I F I C A T I O N O F S T U D I E S
See: methods used in reviews. The reference lists of all identified trials and review articles were checked, and we contacted the trialists, to ask if any studies had been missed.
The update of the Injuries Group review on Human albumin (Albumin 2004) also found new papers that were relevant for this review. The major SAFE trial (SAFE 2004) was published after the search was done but, the reviewers being aware of its publication, it was also considered and was found to meet the inclusion criteria.
Full details of the search strategies used can be obtained from the Injuries Group Trials Search Co-ordinator.
M E T H O D S O F T H E R E V I E W
Allocation concealment was scored as described by Schulz (Schulz 1995) . In particular, the presence of solutions in identical containers was only taken to mean adequate concealment if the fluid containers were used sequentially.
Information on blinding and loss to follow-up was collected but not scored.
As a result of comments on the previous version of this review, trials were stratified by type of fluid rather than type of original injury.
Relative risk (RRs) and 95% confidence interval (95% CI) were calculated for each study using a fixed effects model. Each comparison was then inspected visually for evidence of heterogeneity and a chi-squared test performed. If there was no evidence of heterogeneity (visually or with a p value < 0.1) the trials were pooled within each type of fluid, but not combined between type of fluid.
Trials with allocation concealment judged as inadequate were then excluded and the calculations repeated.
D E S C R I P T I O N O F S T U D I E S
There were 53 trials meeting the inclusion criteria for study design, participants and interventions. We were able to obtain data on deaths for 46 of these. Details of the remaining trials are also reported in the Table of Included Studies for completeness.
Reasons for exclusion of trials were: the use of a cross-over design, testing a resuscitation algorithm, giving the control group oral fluids, the intervention being directed to the maintenance of serum albumin levels, for haemodilution, for fluid loading and for the reduction of intracranial pressure (see Table of Excluded Studies).
Of the 46 randomised controlled trials with data on deaths, the quality of allocation concealment was adequate in six trials and unclear in most of the others.
There were 42 comparisons of colloids and crystalloids (add-on colloid), nine comparisons of colloid in hypertonic crystalloid with isotonic crystalloid, and three comparisons of colloid with hypertonic crystalloid (see Table of Included Studies).
M E T H O D O L O G I C A L Q U A L I T Y
In general, the design of studies was not well reported. This is reflected in the number of unclear scores given for allocation concealment. We also collected information on blinding and loss to follow-up. Blinding was not well reported and loss to follow-up was generally small. The characteristics for each trial are listed in the Table of Included studies.
R E S U L T S
Colloids compared to crystalloids
Albumin or plasma protein fraction Twenty trials reported data on mortality, including a total of 7576 patients. The pooled RR from these trials was 1.02 (95% CI 0.93 to 1.11). When the one trial with poor quality allocation concealment (Lucas 1978) was excluded, the pooled RR was 1.01 (95% CI 0.92 to 1.01).
Hydroxyethyl starch
Ten trials compared hydroxyethyl starch with crystalloids, including a total of 374 randomised participants. The pooled RR was 1.16 (95% CI 0.68 to 1.96).
Modified gelatin
Seven trials compared modified gelatin with crystalloid, including a total of 346 randomised participants. The pooled RR was 0.54 (95% CI 0.16 to 1.85).
Dextran
Nine trials compared dextran with a crystalloid, including a total of 834 randomised participants. The pooled RR was 1.24 (95% CI 0.94 to 1.65).
Colloids in hypertonic crystalloid compared to isotonic crystalloid
One trial compared albumin and hypertonic saline with isotonic crystalloid. Its relative risk of death was 0.50 (0.06 to 4.33).
Eight trials compared dextran in hypertonic crystalloid with isotonic crystalloid, including 1283 randomised participants. The pooled RR was 0.88 (0.74 to 1.05).
Colloids in isotonic crystalloid compared to hypertonic crystalloid
Three trials compared colloids in isotonic crystalloid with hypertonic crystalloid. In two of these, where the colloid was either gelatin or starch, there were no deaths in either group. In the remaining trial, with 38 participants, there was a relative risk of death of 7.00 (0.39 to 126.93) for use of colloid, based on three deaths in the treatment group and none in the control group.
D I S C U S S I O N
This systematic review synthesises the evidence from randomised controlled trials comparing colloid and crystalloid fluid resuscitation across a wide variety of clinical conditions. The review has been updated and extensively revised to take into account the comments made since it was first published. In particular, several commentators pointed out that it is inappropriate to combine effect estimates from studies of different colloids. For example, it was argued that large molecular weight colloids such as hydroxyethyl starch may be better retained in the vascular compartment than albumin and gelatins, and would therefore be more likely to show a favourable effect on mortality (Gosling 1998). In response to these concerns, the review has been stratified by type of colloid. However, the pooled relative risks fail to show a mortality benefit for resuscitation with any type of colloid.
There was a trend towards a favourable effect on mortality for colloids in hypertonic crystalloid, compared to isotonic crystalloids. Nevertheless, the results are compatible with the play of chance.
Common to all meta-analyses, this systematic review may have included studies whose interventions and patient characteristics are sufficiently incomparable that the calculation of a summary effect measure may be questioned. The resuscitation regimen differed between trials. Some trials randomised participants to an initial quantity of colloid or crystalloid, and then proceeded with some form of standard resuscitation for all participants. Other trials resuscitated with the allocated fluid to pre-determined end-points, either resuscitation end-points, or in the case of trauma, until corrective surgery. In addition, the type of colloid or crystalloid, the concentration, and the protocol to determine the quantity of fluid varied. Despite these differences, all participants were in need of volume replacement, and we believe that this variation in the intervention would have an impact on the size of the effect, rather than on its direction.
As regards the effects of albumin versus crystalloid, most of the information (as indicated by the weighting in the meta-analysis) was provided by the SAFE trial. The SAFE trial used central randomisation with a minimisation algorithm to ensure balance on known potential confounders. Blinding was assured through the use of specially designed masking cartons and specially designed and manufactured administration sets. The authors report that the effectiveness of the blinding was confirmed in a formal study before the trial was initiated. In brief, this was a well-conducted, high-quality trial. There were 726 deaths (20.9%) in the albumintreated group and 729 deaths (21.1%) in the saline-treated group (RR of death 0.99; 95% CI 0.91 to 1.09). Although even this large trial was unable to confirm or refute the possibility of a modest benefit or harm from albumin, it has provided some reassurance that any hazard from albumin, if indeed there is any, is unlikely to be as extreme as was suggested by the results from the previously published (now here updated) meta-analysis of much smaller trials. The pooled relative risk for death with albumin in this updated meta-analysis is now 1.02 (0.93 to 1.11). It is important to note that the effect estimate from the SAFE trial is entirely consistent with the results of previous trials of albumin in hypovolaemia and there is no significant heterogeneity (I 2 =0%, p=0.46).
The results of this updated meta-analysis have important policy implications. There is still no evidence that colloids are superior to crystalloids as a treatment for intravascular volume resuscitation in critically ill patients. Importantly, the SAFE trial also provided no evidence of any other clinical advantages from using albumin. It also debunked the belief, from pathophysiological inference, that very large volumes of crystalloid must be administered to reach the same resuscitation end-points as can be achieved using much smaller volumes of colloid. In the SAFE trial, the ratio of albumin administered to saline administered was approximately 1:1.4. Colloids, in particular albumin, are considerably more expensive than crystalloids, and albumin is a blood product and so carries at least a theoretical infectious disease risk. The economic opportunity cost of on-going colloid use, particularly albumin use, is likely to be considerable and for this reason its on-going use in this context is unjustified.
A U T H O R S ' C O N C L U S I O N S
Implications for practice
There is no evidence from randomised controlled trials that resuscitation with colloids, instead of crystalloids, reduces the risk of death in patients with trauma, burns or following surgery. As colloids are not associated with an improvement in survival, and further, colloids are considerably more expensive than crystalloids, it is hard to see how their continued use outside the context of randomised controlled trials in subsets of patients of particular concern, can be justified.
Implications for research
Future trials may need to concentrate on specific sub-groups of patients to identify people who may benefit from colloids rather than crystalloids.
P O T E N T I A L C O N F L I C T O F I N T E R E S T
None known.
A C K N O W L E D G E M E N T S
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S O U R C E S O F S U P P O R T
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T A B L E S
Characteristics of included studies
Study Boldt 1986
Methods Randomised controlled trial, using sealed opaque envelopes. Information on allocation concealment was obtained on contact with the authors. Blinding and loss to follow-up not mentioned.
Participants 55 patients undergoing elective aorto-coronary bypass surgery. Exclusion criteria were ejection fraction < 50% and LVEDP > 15 mmHg.
Interventions 1) 300ml 20% human albumin solution (n=15).
2) 500ml 3% hydroxyethylstarch (n=13).
3) 500ml 3.5% gelatine (n= 14).
4) No colloid (n=13).
Outcomes Haemodynamic variables were measured. Deaths not reported.
Notes
Follow-up until discharge from intensive care.
Allocation concealment B -Unclear
Study Boldt 1993
Methods Randomised controlled trial. Allocation concealment by sealed opaque envelopes (information from author).
Blinding and loss to follow-up not mentioned.
Participants 75 men undergoing elective aortocoronary bypass grafting, who had a pulmonary capillary wedge pressure of less than 5 mmHg after induction of anaesthesia.
Interventions 1) 5% albumin (n=15).
2) 6% HES, mean molecular weight 450,000 (n=15).
3) 6% HES, mean molecular weight 200,000 (n=15). 4) 3.5% gelatin (n=15).
5) No colloid (n=15).
Fluid used through operation and on intensive care post-op.
Outcomes
Deaths not reported, author confirmed there were no deaths.
Notes Follow-up to 1 day.
Allocation concealment B -Unclear
Study Boldt 2001
Methods Randomised controlled trial, using a closed-envelope system. Participants 100 patients undergoing major abdominal surgery.
Interventions 1) Ringer's lactate (n=25).
2) 6% HES, mean molecular weight 200kDa, degree of substitution 0.5 (n=25).
3) 6% HES, mean molecular weight 130kDa, degree of substitution 0.4 (n=25). 4) 4% modified fluid gelatin, molecular weight 35kDA (n=25 
Allocation concealment B -Unclear
Study Lucas 1978
Methods Randomised controlled trial. Randomisation was based on the last digit of each patient's case number.
Participants 52 seriously injured patients.
Interventions 1) Standard resuscitation regimen ('balanced electrolyte', blood, fresh frozen plasma) plus salt poor albumin, maximum 150g during surgery and 150g per day for the next 5 days (n=27).
2) Standard resuscitation regimen as above (n=25).
Outcomes
Deaths reported in some patients.
Notes
In the final report of 94 randomised patients deaths were not reported. However, in this preliminary report of 52 injured patients deaths were reported.
Allocation concealment C -Inadequate
Study Mattox 1991
Methods Quasi-randomised, allocation by alternation. Double-blind. 2 patients excluded from the analysis as code of fluid lost.
Participants
Participants were pre-hospital trauma victims attended to by emergency personnel within an hour of injury, who had systolic blood pressure of 90m mmHg or less and were 16 years or older. 72% of participants had sustained penetrating trauma. Interventions 1) 5mL/kg polygeline (n=10).
2) 5mL/kg 7.2% saline (n=10). Allocated fluid given post-op over one hour. All patients subsequently receive polygeline and red blood cells.
Outcomes
Haemodynamic variables.
Death. Notes
Follow-up to discharge from intensive care.
Allocation concealment B -Unclear
Study McNulty 1993
Methods Randomised controlled trial. Method of allocation concealment not described.
Blinding not mentioned. No loss to follow-up.
Participants
Patients following elective cardiopulmonary bypass.
Interventions 1) 5% albumin and cell-saved blood (n=14).
2) Plasmalyte and cell-saved blood (n=14). Allocated fluid used as part of fluid volume replacement.
Outcomes Deaths not reported. Study was designed to look at the effect of protein infusion on the accuracy of a haematocrit measuring device. Notes Length of follow-up unspecified.
Allocation concealment B -Unclear
Study Metildi 1984
Methods Randomised controlled trial.
Participants
Participants were admissions to an intensive care and a trauma unit with adult respiratory distress syndrome and established pulmonary failure. Included both trauma and non-trauma patients.
Interventions 1) 5% salt-poor albumin (n=20).
2) Ringer's lactate (n=26). Allocated fluid was used throughout resuscitation, and if an operation was required the allocated fluid was used for volume replacement before and during the operation.
Outcomes
Deaths reported.
Notes Follow-up to discharge.
Allocation concealment B -Unclear
Study
Modig 1983
Methods Quasi-randomised controlled trial, allocation by admission date.
Participants
Participants were trauma admissions to an emergency department with a systolic blood pressure of less than 70mmHg. Age range was 20-58 years.
Interventions 1) Dextran-70 in Ringer's lactate (n=12).
2) Ringer's lactate. (n=11) Allocated fluids were given as the initial resuscitation fluid on admission to the emergency department, and continued as needed until after the 6th day when major reconstructive surgery was undertaken.
Outcomes Deaths reported. Development of respiratory distress syndrome.
Notes
Follow-up to definitive reconstructive surgery.
Allocation concealment C -Inadequate
Study Nagy 1993
Methods Randomised controlled trial, contact with author showed it was an open label study.
Participants
Participants were adult admissions to a trauma unit, with measurable systolic blood pressure less than 90 mmHg.
Interventions 1) Pentastarch in 0.9% NaCl (n=21).
2) Ringer's lactate (n=20). Allocated fluid was used throughout resuscitation with the exception that colloid patients recieved a maximum 4L of pentastarch, after which Ringer's lactate was given.
Outcomes Deaths were not reported. Haemodynamic variables.
Allocation concealment C -Inadequate
Study Ngo 2001
Methods Randomised controlled trial, opaque envelopes containing only treatment pack number.
Participants 230 children with dengue shock syndrome. Outcomes Deaths.
Intestinal oedema formation. Notes Follow-up period was unspecifed.
Allocation concealment B -Unclear
Study Rackow 1983
Methods Randomised controlled trial, allocation concealment unclear.
Participants
Participants were aged 54 to 97, and had any one of the following pre-determined indicators of shock: systolic blood pressure of 90 mmHg or less, a cardiac index of less than 2.2 L./min.m2, a serum arterial lactate greater than 18mg/dl and WP less than 15mmHg.
Interventions 1) 6% hydroxoethyl starch (n=9).
2) 5% albumin (n=9).
3) 0.9% saline. (n=8). Allocated fluid was given as needed until the end of resuscitation.
Outcomes Deaths reported. Fluid balance. Notes Follow-up to discharge from hospital.
Allocation concealment B -Unclear
Study
Rocha e Silva 1994
Participants
Participants were admissions to the emergency room, with a systolic blood pressure of 90 mmHg or less and were 16 years of age or older.
Interventions
Colloid group received 6% dextran-70 in 7.5% NaCl; crystalloid group received Ringer's lactate. Allocated fluid was used for the first intravenous infusion only.
Outcomes
Death was the main outcome measure, but the data are unpublished.
Notes
Follow-up to 30 days. By April 1994, 125 patients had been entered into the study. 
Allocation concealment B -Unclear
Study
Allocation concealment B -Unclear
Study Vassar 1990
Methods Randomised controlled trial, allocation concealment unclear. Double blind study (solutions prepared in identical containers).
No loss to follow-up.
Participants
Participants were emergency department admissions with trauma and a systolic blood pressure below 80mmHg and were 18 years or older.
Study Vassar 1993b
Methods Randomised controlled trial, allocation concealed by sequential use of coded identical containers. Double blind study. 39/233 patients excluded as deemed not to meet eligibility criteria, unclear from which groups.
Participants
Participants were pre-hospital trauma cases undergoing helicoptor transport to an emergency centre, had a systolic blood pressure of 100mmHg or less and were 18 years or older. Exclusions: asystolic, undergoing CPR, lack sinus complex on ECG, more than 2 hours after trauma, pregnant, preexisting seizures, bleeding disorder, hepatic, cardiac or renal disease.
Interventions 1) 12% dextran70 in 7.5% saline. (n=49) 2) 6% dextran 70 in 7.5% saline. (n=50) 2) Ringer's lactate (n=14). Allocated fluid was used during operation for maintenence of pre-defined physiological parameters, and the resuscitation was continued with the allocated fluid until the day following the operation. This was followed by 5% dextrose in half-normal saline, with potassium chloride as needed. 
Allocation concealment B -Unclear
Study
Zetterstrom 1981b
Methods The patients were randomly divided into two groups. Allocation concealment was by sealed opaque envelopes (information supplied by author). 
Characteristics of excluded studies (Continued )
A
